Science Explorer Back to mapMap
Discussion
Institution · Northwest Medical Specialties

Most cited papers from Northwest Medical Specialties

Northwest Medical Specialties

What are the most cited papers from Northwest Medical Specialties?

The most cited paper from Northwest Medical Specialties is "Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer" (Gabriel N. Hortobágyi et al., 2016), with 2,066 citations. Next come "Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia" (904) and "Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial" (872).

Showing 50 of 60 papers. Every paper with more than 100 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer Gabriel N. Hortobágyi et al. · New England Journal of Medicine Open access 8 Oct 2016 2,066
2 Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia John C. Byrd et al. · New England Journal of Medicine Open access 8 Dec 2015 904
3 Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial David J. Kuter et al. · The Lancet Feb 2008 872
4 Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases Fred Saad, Janet Elizabeth Brown, Catherine H. Van Poznak et al. · Annals of Oncology Open access 11 Oct 2011 825
5 Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA Richard Burnham Lanman, Stefanie Mortimer, Oliver A. Zill et al. · PLoS ONE Open access 16 Oct 2015 721
6 IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome Laura Belloni, Lena Allweiss, Francesca Guerrieri et al. · Journal of Clinical Investigation Open access 17 Jan 2012 579
7 Platelet Activation in Obese Women Giovanni Davı̀, Maria Teresa Guagnano, Giovanni Ciabattoni et al. · JAMA 23 Oct 2002 542
8 Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial Sung‐Bae Kim et al. · The Lancet Oncology Open access 8 Aug 2017 480
9 Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer Harry D. Bear, Gong Tang, Priya Rastogi et al. · New England Journal of Medicine Open access 26 Jan 2012 473
10 Activation of SAPK/JNK by TNF Receptor 1 Through a Noncytotoxic TRAF2-Dependent Pathway Gioacchino Natoli, Antonio Costanzo, Angelo Ianni et al. · Science 10 Jan 1997 457
11 Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer Mary Lenora Disis, Matthew Hiram Taylor, Karen L. Kelly et al. · JAMA Oncology Open access 24 Jan 2019 437
12 Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial Angelo Di Leo et al. · The Lancet Oncology 7 Dec 2017 389
13 A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas Jeffrey R. Infante, Bradley G. Somer, Joon Oh Park et al. · European Journal of Cancer 7 Jun 2014 376
14 Viable Embryos from Injection of Round Spermatids into Oocytes Jan Tesařík, Carmen E. Mendoza, J Testart · New England Journal of Medicine 24 Aug 1995 354
15 Localization of distinct F2-isoprostanes in human atherosclerotic lesions. Domenico Praticò, Luigi Iuliano, Alessandro Mauriello et al. · Journal of Clinical Investigation Open access 15 Oct 1997 344
16 Evaluation of the Transfer and Expression in Mice of an Enzyme-Encoding Gene Using a Human Adenovirus Vector Leslie D. Stratford-Perricaudet, Massimo Levrero, Jean-François Chassé et al. · Human Gene Therapy Oct 1990 325
17 Hepatic expansion of a virus-specific regulatory CD8+ T cell population in chronic hepatitis C virus infection Daniele Accapezzato, Vittorio Francavilla, Marino Paroli et al. · Journal of Clinical Investigation Open access Apr 2004 302
18 Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial Saad Zafar Usmani et al. · The Lancet Haematology Open access117 authors 18 Jul 2019 249
19 Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial Arlene Chan et al. · Clinical Breast Cancer Open access 5 Oct 2020 221
20 Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study Irene Braña, Antonio Calles, Patricia Mucci LoRusso et al. · Targeted Oncology 15 Jun 2014 216
21 Mutant p53 Enhances Nuclear Factor κB Activation by Tumor Necrosis Factor α in Cancer Cells Lilach Weisz, Alexander Damalas, Michalis Liontos et al. · Cancer Research 15 Mar 2007 201
22 The hepatitis B virus X gene induces p53-mediated programmed cell death Paolo Chirillo, Sabrina Pagano, Gioacchino Natoli et al. · Proceedings of the National Academy of Sciences Open access 22 Jul 1997 199
23 Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study Funda Meric‐Bernstam et al. · The Lancet Oncology Open access 15 Nov 2022 198
24 Immediate Antioxidant and Antiplatelet Effect of Atorvastatin via Inhibition of Nox2 Pasquale Pignatelli, Roberto Carnevale, Daniele Pastori et al. · Circulation Open access 22 May 2012 191
25 Effectiveness of a Community-Based Multifactorial Intervention on Falls and Fall Risk Factors in Community-Living Older Adults: A Randomized, Controlled Trial Anne Shumway‐Cook, Ilene F. Silver, Mary LeMier et al. · The Journals of Gerontology Series A Open access Dec 2007 190
26 Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results John C. Byrd et al. · Blood Open access 26 Dec 2019 179
27 Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study Rashmi Krishna Murthy, Virginia F. Borges, Alison Katherine Conlin et al. · The Lancet Oncology 24 May 2018 174
28 Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology Nicole M. Kuderer, Kimberly A. Burton, Sibel H. Blau et al. · JAMA Oncology Open access 19 Dec 2016 172
29 Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2 -Positive Metastatic Breast Cancer Virginia F. Borges, Cristiano Ferrario, Nathalie Aucoin et al. · JAMA Oncology Open access 28 Jun 2018 169
30 Circadian variation in the frequency of ischemic stroke. C. Argentino, Danilo Toni, Maurizia Rasura et al. · Stroke Open access Mar 1990 167
31 Antiplatelet treatment with ticlopidine in unstable angina: A controlled multicenter clinical trial FRANCESCO BALSANO, PAOLO RIZZON, Francesco Violi et al. · Circulation 1990 162
32 High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining Daniel E. Campton, Arturo B. Ramirez, Joshua J. Nordberg et al. · BMC Cancer Open access 5 May 2015 156
33 Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial Harry D. Bear et al. · The Lancet Oncology Open access 10 Aug 2015 154
34 gp91phox-Dependent Expression of Platelet CD40 Ligand Pasquale Pignatelli, Valerio Sanguigni, Lorenzo Lenti et al. · Circulation Open access 13 Jul 2004 154
35 Telehealth in Oncology: ASCO Standards and Practice Recommendations Robin T. Zon, Erin B. Kennedy, Kerin B. Adelson et al. · JCO Oncology Practice 28 Jul 2021 152
36 Resistance to Fas-mediated apoptosis in human hepatoma cells. Gioacchino Natoli, Angelo Ianni, Antonio Costanzo et al. · PubMed 21 Sep 1995 147
37 Hepatitis B virus pX activates NF-kappa B-dependent transcription through a Raf-independent pathway Paolo Chirillo, Matteo Falco, Prem Puri et al. · Journal of Virology Open access 1996 147
38 Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. Luana Mancarella et al. · PubMed Aug 2007 142
39 p63 and p73 Transactivate Differentiation Gene Promoters in Human Keratinocytes Vincenzo De Laurenzi, Antonello Rossi, Alessandro Terrinoni et al. · Biochemical and Biophysical Research Communications Jun 2000 135
40 Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study G NERISERNERI, SERGIO COCCHERI, Ettore Marubini et al. · European Heart Journal 26 Aug 2004 133
41 Relation of Cardiac Complications in the Early Phase of Community-Acquired Pneumonia to Long-Term Mortality and Cardiovascular Events Roberto Cangemi et al. · The American Journal of Cardiology 22 May 2015 128
42 The Combination of Insulin-Like Growth Factor I and Insulin-Like Growth Factor-Binding Protein-3 Reduces Insulin Requirements in Insulin-Dependent Type 1 Diabetes: Evidence forin VivoBiological Activity1 David R. Clemmons, Alan Charles Moses, M J McKay et al. · The Journal of Clinical Endocrinology & Metabolism Open access Apr 2000 128
43 Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis Valentina Germano, Andrea Picchianti Diamanti, G Baccano et al. · Annals of the Rheumatic Diseases Open access 14 Sep 2005 122
44 Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability—a randomized, placebo-controlled, 3-month trial Charles A. Birbara, Anthony D Puopolo, David Muñoz et al. · Journal of Pain Open access Aug 2003 121
45 Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1) Aditya Bardia, Sara A. Hurvitz, Angela M. DeMichele et al. · Clinical Cancer Research Open access 15 Mar 2021 119
46 Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence Donald M. Gleason, Jacques G. Susset, Charles Michael White et al. · Urology Sep 1999 119
47 Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. FRANCESCO BALSANO, SERGIO COCCHERI, Arnaldo Libretti et al. · PubMed Jul 1989 118
48 Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations Priscilla Kaliopi Brastianos et al. · Journal of Clinical Oncology Open access 26 Oct 2022 114
49 Ultrasound Elastography Assessment of Skin Involvement in Systemic Sclerosis: Lights and Shadows Annamaria Iagnocco, OLGA KALOUDI, Chiara Perella et al. · The Journal of Rheumatology Open access 15 Jun 2010 113
50 Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer Guy Jérusalem, Richard H. De Boer, Sara A. Hurvitz et al. · JAMA Oncology Open access 3 Jun 2018 112

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.